Melissa Wisdom Named Managing Director of Juul Labs in UK.

Nov.13.2024

Juul Labs appoints Melissa Wisdom as Managing Director for UK operations, aims to reduce tobacco harm with innovative products.

In recent days, Juul Labs announced on its official website that Melissa Wisdom will be taking on the role of Managing Director, responsible for overseeing Juul Labs' current and future business operations in the United Kingdom.

It is reported that Melissa previously served as the Chief Commercial Officer at Stonegate Group, where she was responsible for sales, market expansion, and overall business functions. She also held the position of Commercial Director at Diageo, a leading beverage company, and has held senior positions at various well-known domestic and international brands.

Melissa stated, "Becoming the Director General of Juul Labs is an exciting opportunity for me to contribute to the company's bold vision for the future - achieving long-term success through responsible innovation and investment in high-quality, scientifically supported products.

Juul Labs CEO KC Crosthwaite said, "With the introduction of new legislation in the UK and evolving regulatory environments in multiple markets, Melissa's leadership will play a crucial role in our efforts to reduce the harms of tobacco, particularly by providing high-quality product technology to adult smokers to help them stay away from traditional tobacco.

References:

[1] JUUL LABS NAMES NEW MANAGING DIRECTOR, MELISSA WISDOM

Also Read:

[1] Juul and Altria settlement payments begin as some users confirm payments received

[2] JUUL Receives FDA Approval to Resume Product Sales

[3] FDA Revokes Marketing Denial Order for JUUL E-cigarettes

[4] JUUL's New Flavors: altpods Compatible Pods Launch in Japan

#Europe #Open system e-cigarettes #United Kingdom #Major companies

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn

Notice

1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

Copyright

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

AI Assistance Disclaimer

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

ZYN Nicotine Pouches Seek MRTP Authorization; FDA Sets January Meeting

The U.S. FDA has scheduled a Tobacco Products Scientific Advisory Committee (TPSAC) meeting for January 22, 2026, to review Swedish Match USA’s Modified Risk Tobacco Product (MRTP) applications for 20 ZYN nicotine pouch products. Although the products gained PMTA authorization in early 2025, MRTP approval is required for marketing them with reduced-risk claims.

Nov.24 by 2FIRSTS.ai

South Korea Again Delays Tobacco Business Act Amendment on Synthetic Nicotine

South Korea’s amendment to the Tobacco Business Act, which would classify synthetic nicotine vapes and vape liquids as “tobacco” for regulatory and taxation purposes, has been delayed once again. Despite the government stressing its urgency due to youth access and risks of illicit drug mixing, both ruling and opposition parties at the Legislation and Judiciary Committee meeting agreed that the bill requires further discussion.

Nov.13 by 2FIRSTS.ai

RLX Technology Inc. (NYSE: RLX) Q3 2025 Financial Results: Net Revenue US$158.6 Million; International Business Accounts for 72%

RLX Technology Inc. (NYSE: RLX) announced its unaudited financial results for the third quarter of 2025. The company reported net revenue of RMB 1.13 billion, up 49.3% year-on-year, and adjusted net profit of RMB 295.4 million, up 1.4% quarter-on-quarter. International business contributed 72% of total revenue, reflecting robust financial performance and continued shareholder returns.

Nov.14

HSSP INTL signs agreement with COTY to expand e-cigarette business in Middle East and Australia

HSSP INTL(03626.HK) partners with COTY to establish e-cigarette venture in UAE, expand distribution of Heaven Gifts brand.